Myelodysplastic Syndromes: all 2,165 studies
Page 12 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDSSuspendedNCT04485065Phase 1
- Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy VolunteersCompletedNCT04484532Early Phase 1
- Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic SyndromesNo longer availableNCT04484363
- Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDSActive, not recruitingNCT04482894Not applicable
- TPO-Mimetic Use in Children for Hematopoietic FailureCompletedNCT04478227Early Phase 1
- A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell TransfusionsCompletedNCT04477850Phase 2
- A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSTerminatedNCT04477291Phase 1
- Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
- HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell TransplantationWithdrawnNCT04464889Phase 1
- A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04443751Phase 1
- Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationCompletedNCT04439006Phase 1
- JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationCompletedNCT04429191Phase 1
- Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04402541Phase 1
- Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeActive, not recruitingNCT04401748Phase 3
- Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.Active, not recruitingNCT04399018
- Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)WithdrawnNCT04395092Phase 2
- MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic MalignanciesStatus unknownNCT04370457Not applicable
- Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant CyclophosphamideWithdrawnNCT04361058Phase 1
- A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell AllograftsWithdrawnNCT04331483Not applicable
- Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host DiseaseTerminatedNCT04328714Phase 1
- Panobinostat Maintenance After HSCT fo High-risk AML and MDSTerminatedNCT04326764Phase 3
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)CompletedNCT04326023
- Sterile Inflammation and Molecular Aberrations in MDSStatus unknownNCT04313231
- Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaWithdrawnNCT04296214
- Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCTActive, not recruitingNCT04284228Phase 1/2
- TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCTActive, not recruitingNCT04281199Phase 1
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)SuspendedNCT04278768Phase 1/2
- CPX-351 in Higher Risk Myelodysplastic SyndromesCompletedNCT04273802Phase 1/2
- A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)WithdrawnNCT04264806Phase 2
- AML/MDS Drug Sensitization by in Vivo Chemotherapy AdministrationActive, not recruitingNCT04263181
- Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingNCT04262843Phase 2
- Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04250051Phase 1
- A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentCompletedNCT04241549Phase 1
- Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute LeukemiaActive, not recruitingNCT04232241Phase 2
- A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesActive, not recruitingNCT04227847Phase 1
- Enhanced Palliative Care in MDS and AMLStatus unknownNCT04226768Not applicable
- Trial Testing Safety of IL-21 NK Cells for Induction of R/R AMLCompletedNCT04220684Phase 1
- SNS-301 Monotherapy in High Risk MDS and CMMLWithdrawnNCT04217720Phase 2
- Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health CareCompletedNCT04212390
- ATG Plus PTCy vs ATG for CGVHD ProphylaxisActive, not recruitingNCT04202835Phase 2
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04202003Phase 1/2
- Resiliency in Older Adults Undergoing Bone Marrow TransplantCompletedNCT04188678
- Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124WithdrawnNCT04176653Phase 1
- An European Platform for Translational Research in Myelodysplastic SyndromesStatus unknownNCT04174547
- NTX-301 in MDS/AMLCompletedNCT04167917Phase 1
- Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell TransplantActive, not recruitingNCT04167683
- Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDSTerminatedNCT04166929Phase 2
- Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeTerminatedNCT04160052Phase 1/2
- CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT04156256Early Phase 1
- Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeActive, not recruitingNCT04128748Phase 1/2
- Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk MyelodysplasiaWithdrawnNCT04128020Phase 1
- Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With MyelodysplasiaStatus unknownNCT04110925Not applicable
- CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.WithdrawnNCT04109690Phase 1/2
- Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment ResultsStatus unknownNCT04060485
- Observational Study Towards the Impact of Newly Started Treatment in MDS on QoLCompletedNCT04053933
- A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSWithdrawnNCT04044209Phase 2
- A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in KoreaCompletedNCT04036448
- A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyActive, not recruitingNCT04027309Phase 3
- PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
- RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic SyndromeTerminatedNCT04021368Phase 1
- CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCompletedNCT04017546Phase 1
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaWithdrawnNCT04013880Phase 1/2
- Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT04013685Phase 1
- Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and BiomarkerStatus unknownNCT04003220
- A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRCStatus unknownNCT03978364Phase 3
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1
- Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic TransplantCompletedNCT03961919Phase 2
- Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCTWithdrawnNCT03939585Phase 1
- ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantCompletedNCT03932643Phase 1
- CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic SyndromeWithdrawnNCT03929211Phase 1/2
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSActive, not recruitingNCT03927261Phase 1
- Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDSTerminatedNCT03920657Phase 2
- A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
- Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic SyndromesActive, not recruitingNCT03906695Phase 1
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)CompletedNCT03904134Not applicable
- SRSF2 Gene Mutation in Patients With t-MDS/AMLCompletedNCT03894852
- Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell AllograftStatus unknownNCT03887156Phase 2/3
- VPA Expanded UCB Transplantation for Treatment of Patients With Hematological MalignanciesCompletedNCT03885947Phase 1
- A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDSTerminatedNCT03884829Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyStatus unknownNCT03873311Phase 4
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationActive, not recruitingNCT03842696Phase 1/2
- Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell TransplantationStatus unknownNCT03836690Phase 1
- Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesCompletedNCT03824080Phase 2
- TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsActive, not recruitingNCT03816319Phase 1
- Effect of Food on Blood Levels of ASTX727CompletedNCT03813186Phase 1
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1
- Early Palliative Care for Patients With Haematological MalignanciesStatus unknownNCT03800095Phase 3
- CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesStatus unknownNCT03795779Early Phase 1
- A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeCompletedNCT03787498Phase 1
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingNCT03770429Phase 1
- A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic SyndromesCompletedNCT03746041Phase 1
- IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeActive, not recruitingNCT03744390Phase 2
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell TransplantActive, not recruitingNCT03739502Phase 2
- Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
- Expanded Access for ACE-011No longer availableNCT03724227